Evidence map›Paper›PMID 42249666›Full record

ArticleHeadache

Suzetrigine as a novel treatment for headache disorders: A case series.

Molly Fensterwald, Jordan Johnson, Angel Moreno, Shawn Conger-Love, Charles Flippen, Chelsea Hesterman, Mollie Johnston, Joshua Kamins, Karla Minota, Peony Pak and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Headache. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Molly FensterwaldDepartment of Neurology, Goldberg Migraine Program, University of California Los Angeles, Los Angeles, California, USA.
Jordan JohnsonDepartment of Neurology, Goldberg Migraine Program, University of California Los Angeles, Los Angeles, California, USA.
Angel MorenoDepartment of Neurology, Goldberg Migraine Program, University of California Los Angeles, Los Angeles, California, USA.
Shawn Conger-LoveDepartment of Neurology, Goldberg Migraine Program, University of California Los Angeles, Los Angeles, California, USA.
Charles FlippenDepartment of Neurology, Goldberg Migraine Program, University of California Los Angeles, Los Angeles, California, USA.
Chelsea HestermanDepartment of Neurology, Goldberg Migraine Program, University of California Los Angeles, Los Angeles, California, USA.
Mollie JohnstonDepartment of Neurology, Goldberg Migraine Program, University of California Los Angeles, Los Angeles, California, USA.
Joshua KaminsDepartment of Neurology, Goldberg Migraine Program, University of California Los Angeles, Los Angeles, California, USA.
Karla MinotaDepartment of Neurology, Goldberg Migraine Program, University of California Los Angeles, Los Angeles, California, USA.
Peony PakDepartment of Neurology, Goldberg Migraine Program, University of California Los Angeles, Los Angeles, California, USA.
Salman HashimDepartment of Neurology, Goldberg Migraine Program, University of California Los Angeles, Los Angeles, California, USA.
Thanh-Liem Huynh-TranDepartment of Neurology, Goldberg Migraine Program, University of California Los Angeles, Los Angeles, California, USA.
Noelle KobayashiDepartment of Neurology, Goldberg Migraine Program, University of California Los Angeles, Los Angeles, California, USA.
Bradley ShaneDepartment of Neurology, Goldberg Migraine Program, University of California Los Angeles, Los Angeles, California, USA.
Andrew CharlesDepartment of Neurology, Goldberg Migraine Program, University of California Los Angeles, Los Angeles, California, USA.
Sinifunanya NwaobiDepartment of Neurology, Goldberg Migraine Program, University of California Los Angeles, Los Angeles, California, USA.

Funding

UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
NCATS NIH HHS UL1 TR001881Wendy and Leonard Goldberg Endowment
6 · The paper itself

Abstract

Suzetrigine is a selective voltage-gated sodium channel blocker that was recently approved by the US Food and Drug Administration for the treatment of acute pain. We retrospectively evaluated the efficacy and tolerability of suzetrigine for the treatment of different headache disorders in patients refractory to standard treatments in an academic headache center. These patients had a variety of headache and facial pain diagnoses, including chronic migraine, medication-overuse headache, trigeminal autonomic cephalalgias, nummular headache, occipital neuralgia, and persistent idiopathic facial pain. Some did not clearly meet any diagnostic criteria. The treatment was generally well tolerated, and most patients reported improvement as measured by patient global impression of change. Suzetrigine is a promising new therapeutic approach that warrants further study for the treatment of headache disorders.

Indexed as

Headache DisordersAdultAgedAmidesAminopyridinesFemaleFuransHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeAmidesAminopyridinesFuranssuzetriginerefractory headachesuzetriginetreatment

Identifiers

PMID42249666
PMCPMC13326962

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.